Clinical Report: Updated Strategies to Reduce Infection Risks in Hematopoietic Cell Transplant Patients
Overview
This international guideline update provides evidence-based recommendations to prevent infectious complications in hematopoietic cell transplant (HCT) recipients. It reflects advances in antimicrobial agents, conditioning regimens, and patient demographics since the 2000 guidelines, addressing a broad spectrum of pathogens and care practices.
Background
Hematopoietic cell transplantation involves infusion of blood- or marrow-derived stem cells and carries significant infectious risk due to immune suppression. Since the original 2000 guidelines, changes such as increased use of reduced-intensity conditioning, older recipients, and alternative donor sources have altered infection risk profiles. Infection remains a leading cause of mortality post-transplant, particularly in allogeneic recipients. These updated guidelines aim to provide a global, evidence-based framework for preventing infections throughout the transplant timeline.
Data Highlights
Infection is the primary cause of death in approximately 8% of autologous and 17–20% of allogeneic HCT recipients. Immune competence is generally considered restored around 24 months post-transplant in patients without graft-versus-host disease (GVHD) or ongoing immunosuppression. The guidelines incorporate new data on multiple pathogens not previously covered, reflecting evolving clinical challenges.
Key Findings
The guidelines cover both autologous and allogeneic HCT recipients, including pediatric and adult patients, and consider myeloablative and reduced-intensity conditioning similarly due to limited comparative data.
Recommendations are graded by strength and quality of evidence using a system developed by IDSA and the US Public Health Service.
Newly included pathogens of clinical relevance include Bordetella pertussis, polyomaviruses BK and JC, hepatitis viruses A, B, and C, human herpesviruses 6, 7, and 8, human metapneumovirus, HIV, tuberculosis, nocardiosis, malaria, and leishmaniasis.
The guidelines address infection prevention from donor selection through post-transplant immune recovery, including vaccination strategies and nosocomial infection prevention.
Recommendations are intended to be adaptable to local epidemiology, resource availability, and practice patterns without dictating rigid standards.
Clinical Implications
Clinicians caring for HCT recipients should integrate these updated, evidence-based recommendations into practice to reduce infectious morbidity and mortality. Awareness of emerging pathogens and tailored prevention strategies according to transplant type, conditioning regimen, and immune status are essential. Coordination among transplant teams, infectious disease specialists, and public health professionals is critical to optimize patient outcomes.
Conclusion
This comprehensive update provides a global, evidence-based framework to guide infection prevention in HCT recipients amid evolving clinical practices and pathogen landscapes. Adherence to these recommendations can improve patient safety throughout the transplant continuum.
References
CIBMTR et al. 2024 -- Strategies for Reducing Infectious Risks in Hematopoietic Cell Transplant Patients: An International Overview
